{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Bosnjak B"],"funding":["Bundesministerium für Bildung und Forschung","Deutsches Zentrum für Infektionsforschung","Niedersächsische Ministerium für Wissenschaft und Kultur","Deutsche Forschungsgemeinschaft"],"pubmed_abstract":["Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients."],"journal":["Frontiers in immunology"],"pagination":["721738"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8387963"],"repository":["biostudies-literature"],"pubmed_title":["Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy."],"pmcid":["PMC8387963"],"pubmed_authors":["Steinbruck L","Bosnjak B","Graalmann T","Ganser A","Forster R","Falk CS","Stahl K","Ritter C","Odak I","Schulz TF","Cornberg M","Blasczyk R","Koenecke C","Wedemeyer HH"],"additional_accession":[]},"is_claimable":false,"name":"Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.","description":"Here, we described the case of a B cell-deficient patient after CD19 CAR-T cell therapy for refractory B cell Non-Hodgkin Lymphoma with protracted coronavirus disease 2019 (COVID-19). For weeks, this patient only inefficiently contained the virus while convalescent plasma transfusion correlated with virus clearance. Interestingly, following convalescent plasma therapy natural killer cells matured and virus-specific T cells expanded, presumably allowing virus clearance and recovery from the disease. Our findings, thus, suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections. If confirmed in larger clinical studies, these data could be of general importance for the treatment of COVID-19 patients.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-08T09:14:16.701Z","creation":"2026-04-07T23:49:32.041Z"},"accession":"S-EPMC8387963","cross_references":{"pubmed":["34456929"],"doi":["10.3389/fimmu.2021.721738"]}}